Ronald  Razmi Profile Picture

Keynote SpeakerRonald Razmi

Cardiologist, Author, McKinsey Consultant, Founder and CEO of Healthcare Software Company, Partner at Healthcare Venture Capital firm

Dr. Ron Razmi is a cardiologist, author, McKinsey consultant, Founder and CEO of healthcare software company, investor and speaker. He is the author of the recently published book “AI Doctor: The Rise of Artificial Intelligence in Healthcare” where he examines how AI can best be used to address the key... Read more

Biography

Dr. Ron Razmi is a cardiologist, author, McKinsey consultant, Founder and CEO of healthcare software company, investor and speaker. He is the author of the recently published book “AI Doctor: The Rise of Artificial Intelligence in Healthcare” where he examines how AI can best be used to address the key issues facing healthcare systems and life sciences companies. He also offers frameworks for development of and investment in health AI tools for corporations, investors, and entrepreneurs. He has been featured on CNBC, ABC, Fox Business, Politico, and other media outlets.

Ron began his career as a cardiologist at the Mayo Clinic and was one of the pioneers in the applications of MRI systems in managing cardiac patients. He is a co-author of the Handbook of Cardiovascular Magnetic Resonance Imaging.

As a McKinsey consultant, Ron advised the world’s top healthcare companies in corporate strategy, M&A and the use of emerging technologies to improve their business models.

Ron Founded and ran Acupera, a population health management software company in 2011. This software platform improves the management of patients with chronic diseases. This platform has been used in the largest health systems in US such as Kaiser Permanente, Montefiore Medical Center, and Ascension Health.

In 2021, he launched the AI Doctor Blog, a blog focused on how AI will impact healthcare in the coming years. He’s a frequent guest on podcasts such as Open Book with Anthony Scaramucci and Health Innovator’s Show and speaker at conferences, including the World Economic Forum, C3 at United Nations General Assembly, Davos of Healthcare, and  Wall Street Journal Health Forum. As a member of the Fast Company’s Executive Board, he publishes articles about the impact of AI on jobs, macroeconomic issues, and the future of technology in society. He also authors guest articles for various publications and has been featured in publications such as Newsweek and Apple News.

Ron completed his medical training at the Mayo Clinic and holds an MBA from the Northwestern University’s Kellogg School of Management.

Popular Talks by Ronald Razmi

  • Investing in health AI

    While everyone is excited about the long-term potential of AI for health and healthcare, not every application will see short-term adoption. Given that private investment time horizons are only a few years, having an informed approach that successfully selects the best short-term use cases will lead to success. How to...

  • AI in life sciences commercial organizations

    While drug discovery gets a lot of the attention when it comes to AI in life sciences, some argue that the most near-term benefits for AI will be for the commercial organization. This spans regulatory filings, social listening, provider interactions, content creation, and more. Still, not all potential applications are...

  • Corporate M&A and VC strategy in the age of AI

    Using artificial intelligence to improve the business model of any company is a topic that the management and the Board should be debating. The buy vs. build vs partner will be a key part of that debate. Corporate development and VC groups will be a major part of this as...

  • Health, wellness and Longevity

    In the last decade, there has been an explosion of interest and tools for health, wellness, and even longevity.  While we are in the early days of apps, wearables, AI-designed supplements, red light therapy, etc, the key question is what is evidence-based and science-backed and what is not? How to improve...

  • AI in Drug Discovery and Development

    Billions of dollars have been invested to accelerate discovery and development of life-saving drugs using AI. While the promise is exciting, the results are still work-in-progress. While technologies that can accelerate clinical trials are showing early ROI, investments in AI for drug discovery have longer time horizon. What is the...

  • AI and jobs

    As it has happened at various times in history, the question of technological progress leading to mass unemployment is once again front and center.  Will AI be different than previous waves of automation and actually lead to millions of newly unemployed people? or, will AI free us up to focus on...

  • Crafting AI strategy in a healthcare organization

    AI is noisy and it is not easy to separate fact from fiction. While the hype is in full throttle,  knowing where to get started, and how, is not easy. AI is not plug and play. Each use case needs to be launched and operationalized in order to see the benefits....